Randomly methylated β-cyclodextrin derivatives enhance taxol permeability through human intestinal epithelial Caco-2 cell monolayer

Journal of Pharmaceutical Sciences

Volumn 100, Issue 11, 2011, Pages 4734-4744

  Fenyvesi, Ferenc ^a   Kiss, Tímea ^a   Fenyvesi, Éva ^b   Szente, Lajos ^b   Veszelka, Szilvia ^c   Deli, Mária A ^c   Váradi, Judit ^a   Fehér, Pálma ^a   Ujhelyi, Zoltán ^a   Tósaki, Árpád ^a   Vecsernyés, Miklós ^a   Bácskay, Ildikó ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b CycloLab Cyclodextrin Research & Development Laboratory Ltd   (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Caco 2 cells; Cyclodextrins; Epithelial delivery permeability; P glycoprotein; Taxol; Tight junction

Indexed keywords

BETA CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; GLYCOPROTEIN P; MACROGOL 4000; MANNITOL; MONOAMINO RANDOMLY METHYLATED BETA CYCLODEXTRIN; PACLITAXEL; RANDOMLY METHYLATED BETA CYCLODEXTRIN; SUCCINYLATED RANDOMLY METHYLATED BETA CYCLODEXTRIN; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN CACO 2; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG PENETRATION; ELECTRIC RESISTANCE; HUMAN; HUMAN CELL;

EID: 80053279097     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22666     Document Type: Article

References (45)

1. Rowinsky EK, Donehower RC. 1995. Paclitaxel (Taxol). New Engl J Med 332:1004-1014.
2. Malingré MM, Beijnen JH, Schellens JHM. 2001. Oral delivery of taxanes. Invest New Drugs 19:155-162.
3. Beijnen JH, Huizing MT, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Giaccone G, Pinedo HM. 1994. Bioanalysis, pharmacokinetics, and pharmacodynamics of a novel anticancer drug paclitaxel (Taxol). Semin Oncol 21:53-62.
4. Fujita H, Okamoto M, Takao A, Mase H, Kojima H. 1994. Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood levels. Gan To Kagaku Ryoho 21:653-658.
5. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. 1993. Taxol: Mechanisms of action and resistance. J Natl Cancer I 15:55-61.
6. Sparreboom A, Van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O. 1997. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035.
7. Alani AWG, Rao DA, Seidel R, Wang J, Jiao J, Kwon GS. 2010. The effect of novel surfactants and Solutol® HS 15 on paclitaxel aqueous solubility and permeability across a Caco-2 monolayer. J Pharm Sci 99:3473-3485.
8. Bilensoy E, Gürkaynak O, Dogan AL, Hincal AA. 2008. Safety and efficacy of amphiphilic β-cyclodextrin nanoparticles for paclitaxel delivery. Int J Pharm 374:163-170.
9. Bhardwaj V, Ankola DD, Gupta SC, Schneider M, Lehr CM, Kumar MN. 2009. PLGA nanoparticles stabilized with cationic surfactant: Safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm Res 26:2495-2503.
10. Agüeros M, Zabaleta V, Espuelas S, Campanero MA, Irache JM. 2010. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J Control Release 145:2-8.
11. Peltier S, Oger JM, Lagarce F, Couet W, Benoît JP. 2006. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res 23:1243-1255.
12. Nornoo AO, Zheng H, Lopes LB, Johnson-Restrepo B, Kannan K, Reed R. 2009. Oral microemulsions of paclitaxel: In situ and pharmacokinetic studies. Eur J Pharm Biopharm 71:310-317.
13. Varma MV, Panchagnula R. 2005. Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 25:445-453.
14. Collnot EM, Blades C, Wempe MF, Hyatt J, Navarro L, Edgar KJ, Schaefer UF, Lehr CM. 2006. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J Control Release 111:35-40.
15. Alcaro S, Ventura CA, Paolino D, Battaglia D, Ortuso F, Cattel L, Puglisi G, Fresta M. 2008. Preparation and characterization molecular modelling and in vitro activity of paclitaxel-cyclodextrin complexes. Bioorg Med Chem Lett 12:1637-1641.
16. Cserháti T, Holló J. 1994. Interaction of taxol and other anticancer drugs with hydroxypropyl-β-cyclodextrin. Int J Pharm 108:69-75.
17. Sharma US, Balasubramanian SV, Straubinger RM. 1995. Pharmaceutical and physical properties of paclitaxel (taxol) complexes with cyclodextrins. J Pharm Sci 84:1223-1230.
18. Bouquet W, Ceelen W, Fritzinger B, Pattyn P, Peeters M, Remon JP, Vervaet C. 2007. Paclitaxel/β-cyclodextrin complexes for hyperthermic peritoneal perfusion-Formulation and stability. Eur J Pharm Biopharm 66:391-397.
19. Kiss T, Fenyvesi F, Bácskay I, Váradi J, Fenyvesi É, Iványi R, Szente L, Tósaki Á, Vecsernyés M. 2010. Evaluation of the cytotoxicity of β-cyclodextrin derivatives: Evidence for the role of cholesterol extraction. Eur J Pharm Sci 40:376-380.
20. Stella VJ, He Q. 2008. Cyclodextrins. Toxicol Pathol 36:30-42.
21. Kiss T, Fenyvesi F, Pásztor N, Fehér P, Váradi J, Kocsán R, Szente L, Fenyvesi É, Szabó G, Vecsernyés M, Bácskay I. 2007. Cytotoxicity of different types of methylated beta-cyclodextrins and ionic derivatives. Pharmazie 62:557-558.
22. Castagne D, Fillet M, Delattre L, Evrard B, Nusgens B, Piel G. 2009. Study of the cholesterol extraction capacity of β-cyclodextrin and its derivatives, relationships with their effects on endothelial cell viability and on membrane models. J Incl Phenom Macro 63:225-231.
23. Arima H, Yunomae K, Hirayama F, Uekama K. 2001. Contribution of P-glycoprotein to the enhancing effects of dimethyl-β-cyclodextrin on oral bioavailability of tacrolimus. J Pharmacol Exp Ther 297:547-555.
24. Arima H, Yunomae K, Morikawa T, Hirayama F, Uekama K. 2004. Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-β-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers. Pharm Res 21:625-634.
25. Fenyvesi F, Fenyvesi É, Szente L, Goda K, Bacsó Z, Bácskay I, Váradi J, Kiss T, Molnár É, Janáky T, Szabó G Jr., Vecsernyés M. 2008. P-glycoprotein inhibition by membrane cholesterol modulation. Eur J Pharm Sci 34:236-242.
26. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
27. Walle UK, Walle T. 1998. Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos 26:343-346.
28. Szakács G, Váradi A, Özvegy-Laczka C, Sarkadi B. 2008. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 13:379-393.
29. Giacomini KM, Huang Shiew-Mei, Tweeedie DJ, Benet LZ, Brouwer KLR, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. 2010. Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
30. Chao AC, Taylor MT, Daddona PE, Broughakk M, Fix JA. 1998. Molecular weight-dependent paracellular transport of fluorescent model compounds induced by palmitoylcarnitine chloride across the human intestinal epithelial cell line Caco-2. J Drug Target 6:37-43.
31. Artursson P, Karlsson J. 1991. Correlation between oral drug absorption in human and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175:880-885.
32. Rubas W, Jezyk N, Grass GM. 1993. Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm Res 10:113-118.
33. Markowska M, Oberle R, Juzwin S, Hsu CP, Gryszkiewicz M, Streeter AJ. 2001. Optimizing Caco-2 cell monolayers to increase throughput in drug intestinal absorption analysis. J Pharmacol Toxicol Methods 46:51-55.
34. Artursson P. 1990. Epithelial transports of drugs in cell culture. I.: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci 79:476-482.
35. Hellinger É, Bakk LM, Pócza P, Tihanyi K, Vastag M. 2010. Drug penetration model of vinblastine-treated Caco-2 cultures. Eur J Pharm Sci 41:96-106.
36. Hosoya K, Ohtsuki S, Terasaki T. 2002. Recent advances in the brain-to-blood efflux transport across the blood-brain barrier. Int J Pharm 248:15-29.
37. Szente L, Vikmon M, Szemán J, Otta K. 1999. Methyl-β-cyclodextrin/paclitaxel aqueous solutions: A tool to test Cremophor-free paclitaxel. STP Pharm Sci 9:243-247.
38. Eckford PD, Sharom FJ. 2008. Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: Effects on ATPase activity, drug binding and transport. Biochemistry 47:13686-13698.
39. Másson M, Loftsson T, Másson G, Stefánsson E. 1999. Cyclodextrins as permeation enhancers: Some theoretical evaluations and in vitro testing. J Control Release 59:107-118.
40. Rosenbaum AI, Zhang G, Warren D, Maxfield FR. 2010. Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells. Proc Natl Acad Sci U S A 107:5477-5482.
41. Wei H, Zheng W, Diakur J, Wiebe LI. 2011. Confocal laser scanning microscopy (CLSM) based evidence for cell permeation by mono-4-(N-6-deoxy-6-amino-β-cyclodextrin)-7-nitrobenzofuran (NBD-β-CyD). Int J Pharm 403:15-22.
42. Lambert D, O'Neill CA, Padfield PJ. 2005. Depletion of Caco-2 cell cholesterol disrupts barrier function by altering the detergent solubility and distribution of specific tight junction proteins. Biochem J 387:553-560.
43. Deli MA,. 2009. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta 1788:892-910.
44. Ventura CA, Tommasini S, Falcone A, Giannone I, Paolino D, Sdrafkakis V, Mondello MR, Puglisi G. 2006. Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin. Int J Pharm 314:37-45.
45. Szejtli J. 1994. Medical applications of cyclodextrins. Med Res Rev 14:353-386.